Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Melanoma 273Carcinoma, Non-Small-Cell Lung 244Carcinoma, Renal Cell 144Neoplasms 99Neoplasm Metastasis 99Squamous Cell Carcinoma of Head and Neck 88Carcinoma, Hepatocellular 87Colorectal Neoplasms 82Lung Neoplasms 77Stomach Neoplasms 59Pancreatic Neoplasms 56Carcinoma, Transitional Cell 50Hodgkin Disease 47Urinary Bladder Neoplasms 42Head and Neck Neoplasms 42Breast Neoplasms 40Ovarian Neoplasms 37Triple Negative Breast Neoplasms 34Small Cell Lung Carcinoma 33Brain Neoplasms 33Sarcoma 32Prostatic Neoplasms 32Glioblastoma 32Kidney Neoplasms 29Recurrence 28Multiple Myeloma 25Esophageal Neoplasms 24Uveal Melanoma 23Skin Neoplasms 23Uterine Cervical Neoplasms 22

Interventions

Lenalidomide 17Dexamethasone 15Calcium Dobesilate 8daratumumab 5dexamethasone acetate 4dexamethasone 21-phosphate 4carfilzomib 4auricularum 4Melphalan 4Leflunomide 3Curcumin 3isatuximab 2iberdomide 2elotuzumab 2Peripheral Blood Stem Cell Transplantation 2PVX-410 vaccine 2Denosumab 2Cyclophosphamide 2Bortezomib 2siltuximab 1selinexor 1sargramostim 1pomalidomide 1poly ICLC 1piperine 1pembrolizumab 1ixazomib 1ibrutinib 1fludarabine phosphate 1fludarabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Smoldering Multiple Myeloma × Nivolumab × Clear all
NCT02903381 2023-06-13

A Phase II Trial If Nivolumab, Lenalidomide and Dexamethasone in High Risk Smoldering Myeloma

Dana-Farber Cancer Institute

Phase 2 Completed
8 enrolled 16 charts
Plasma cell

Smoldering Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡